Michael Staehler is the Head of the Interdisciplinary Centre for Renal Tumours at the Ludwig-Maximilians University of Munich, Germany.

 

He is a member of the Renal Cancer Workgroup of the German Cancer Society. He also serves as a member of the German Guideline Committee on Renal Cancer.

 

Following medical qualification at University of Munich Medical School and gaining experience in general, vascular and thoracic surgery at the University of Regensburg, the University of California in San Francisco and his training in Urology at the Free University, Berlin, he was awarded a PhD for his work on renal cancer at the University of Munich.

 

After joining the Department of Urology, he was appointed Consultant Urologist at Grosshadern Clinics and founded the Interdisciplinary Centre on Renal Tumours in Germany. He is also Head of the Urological Oncology Service for Advanced Genitourinary Cancer and Kidney surgery.

 

Professor Staehler’s main research interest has been the development of novel therapeutics in renal cell carcinoma, particularly in the area of radiation therapy, surgical therapy and novel targeted agents. He is a Medical Advisor to the German Kidney Cancer Association.

 

He is on the editorial board of several journals and Professor Staehler has published more than 220 articles on renal cancer and co-authored six textbooks.

Prof. Michael Staehler has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consultant: Apogepha, Astellas, Aveo, Bayer, BMS, Eisai, Exelixis, EUSAPharm, GlaxoSmithKline, Ipsen, Jansen, MSD, Novartis, Oncorena, Pelloton, Pfizer, Recordati, Roche

 

Honoraria: Apogepha, Astellas, Aveo, Bayer, BMS, Eisai, EUSAPharm, Exelixis, GlaxoSmithKline, Ipsen, Johnson & Johnson, MSD, Novartis, Pelloton, Pfizer, Recordati

 

Research Funding: AstraZeneca, AVEO, Bayer, BMS, Eisai, Exelixis, GlaxoSmithKline, Immatics, Ipsen, Novartis, Pfizer, Roche/Genentech, Wilex